Bank Of New York Mellon Corp Dia Medica Therapeutics Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$1.32 - $1.89 $47,601 - $68,157	36,062 New	36,062 $55.2 Million
Q4 2022 Feb 14, 2023	BUY	$1.13 - $1.62 $40,750 - $58,420	36,062 New	36,062 $56,000
Q2 2022 Aug 15, 2022	SELL	$1.86 - $2.62 $305 - $429	-164 Reduced 0.45%	36,248 $73,000
Q1 2022 May 11, 2022	SELL	$2.29 - $3.88 $30,850 - $52,271	-13,472 Reduced 27.01%	36,412 $91,000
Q3 2021 Nov 12, 2021	BUY	$3.1 - $4.32 $35,960 - $50,112	11,600 Added 30.3%	49,884 $200,000
Q2 2021 Aug 11, 2021	SELL	$4.45 - $9.91 $10,199 - $22,713	-2,292 Reduced 5.65%	38,284 $170,000
Q1 2021 May 13, 2021	SELL	$7.76 - $10.43 $18,073 - $24,291	-2,329 Reduced 5.43%	40,576 $371,000
Q4 2020 Feb 09, 2021	BUY	$4.13 - $10.14 $121,558 - $298,450	29,433 Added 218.48%	42,905 $435,000
Q2 2020 Aug 12, 2020	BUY	$2.6 - $7.32 $35,027 - $98,615	13,472 New	13,472 $93,000

4.22M

8.2K

200

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $118M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.